Capsule Summary Slidesets

Share

Program Content

Activities

  • REACH3
    REACH3: Phase III Trial of Ruxolitinib vs Best Available Therapy in Steroid-Refractory/Dependent, Chronic GVHD
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2020

    Expires: December 08, 2021

  • HOPE-B: AMT-061 in HEMB
    Phase III HOPE-B: Etranacogene Dezaparvovec Gene Therapy in Adults With Severe or Moderately Severe Hemophilia B
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2020

    Expires: December 09, 2021

  • ITP: 1L MMF + Steroids
    FLIGHT: First-line Mycophenolate + Steroids vs Standard Steroid Treatment in Patients With Newly Diagnosed Immune Thrombocytopenia Purpura
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2020

  • ROCKstar
    ROCKstar Phase II Trial of Daily or Twice-Daily Belumosudil (KD025) in Previously Treated Patients With Chronic GVHD
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

    Expires: December 13, 2021

  • BELIEVE: HRQoL Analysis
    BELIEVE: HRQoL Outcomes for Patients With Transfusion-Dependent β-Thalassemia Treated With Luspatercept
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

    Expires: December 13, 2021

  • CLIMB THAL-111/SCD-121
    CLIMB THAL-111/SCD-121: Phase I/II Studies of CTX001 for Transfusion-Dependent β-Thalassemia and Sickle Cell Disease
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2020

    Expires: December 15, 2021

  • Ph I/II: Rilzabrutinib in ITP
    Phase I/II Trial of BTK Inhibitor Rilzabrutinib (PRN1008) for Heavily Pretreated Patients With Immune Thrombocytopenia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2020

    Expires: December 15, 2021

  • Mitapivat Phase I in SCD
    Phase I Dose-Escalation Study of Mitapivat (AG-348) in Patients With Sickle Cell Disease
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2020

    Expires: December 15, 2021

  • Baricitinib in GVHD
    Phase I/II Study of JAK1/2 Inhibitor Baricitinib in Refractory Chronic GVHD
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2020

    Expires: December 16, 2021

  • Itacitinib in GVHD
    GRAVITAS-119: Phase I Study of Itacitinib Plus Calcineurin Inhibitors as Prophylaxis for GVHD
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2020

    Expires: December 17, 2021

Provided by

ProCE Banner

Supporters

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology